Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin-1A anxiolytics: an overview.

J P Feighner1, W F Boyer

  • 1Feighner Research Institute, Encinitas, Calif.

Psychopathology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers.

Biopharmaceutics & drug disposition·2005
Same author

Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression.

International clinical psychopharmacology·2001
Same author

Citalopram treatment of fluoxetine nonresponders.

The Journal of clinical psychiatry·2001
Same author

A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.

Journal of affective disorders·2000
Same author

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.

The Journal of clinical psychiatry·2000
Same author

Overview of antidepressants currently used to treat anxiety disorders.

The Journal of clinical psychiatry·2000
Same journal

Childhood Maltreatment and Psychopathology: The Mediating Roles of Mentalizing and Attachment Styles.

Psychopathology·2026
Same journal

Validation of the Examination of Autistic Intersubjective Experiences (EAIE).

Psychopathology·2026
Same journal

Tourette syndrome and rage attacks - a longitudinal and cross-sectional study.

Psychopathology·2026
Same journal

Depressing temporal experiences: the COVID-19 Pandemic lockdown in Victoria, Australia.

Psychopathology·2026
Same journal

Involuntary hospitalization for treatment: Triangulation of Perspectives of patients, relatives, and professionals.

Psychopathology·2026
Same journal

Depersonalization, Emotion Embodiment, and Alexithymia in the General Population.

Psychopathology·2026
See all related articles

New selective serotonin-1A receptor agonists offer effective generalized anxiety disorder (GAD) treatment with fewer side effects. These 5-hydroxytryptamine-1A (5-HT1A) anxiolytics show no abuse potential or withdrawal symptoms, marking an advance in GAD management.

Area of Science:

  • Pharmacology
  • Neuroscience

Background:

  • Generalized anxiety disorder (GAD) is a common condition often treated with benzodiazepines.
  • Selective serotonin-1A receptor partial agonists represent a novel pharmacologic class for GAD.

Purpose of the Study:

  • To review the unique features, efficacy, and safety of selective 5-hydroxytryptamine-1A (5-HT1A) receptor agonists in GAD treatment.
  • To compare these novel anxiolytics with traditional benzodiazepine therapies.

Main Methods:

  • Review of existing literature on 5-HT1A anxiolytics including buspirone, gepirone, ipsapirone, and SM-3997.
  • Analysis of pharmacologic properties, clinical efficacy, side effect profiles, and long-term outcomes.

Main Results:

  • 5-HT1A anxiolytics demonstrate efficacy in GAD with no cross-tolerance to alcohol or benzodiazepines.

Related Experiment Videos

  • These agents lack abuse potential, withdrawal symptoms, and psychomotor impairment.
  • Common side effects include nausea, headache, and dizziness; onset of action is slower than benzodiazepines.
  • Buspirone shows excellent long-term maintenance and prophylactic properties.

    • Conclusions:

    • Selective 5-hydroxytryptamine-1A receptor agonists offer a distinct and advantageous therapeutic option for GAD.
    • Their favorable safety profile and lack of abuse potential represent a significant advancement in anxiety disorder pharmacotherapy.